Prevalence of Delayed Chemotherapy Associated Nausea
CINrate
Delayed Chemotherapy-induced Nausea: A Multi-center Prevalence Survey in Adult Oncology Patients in Clinical Practice
1 other identifier
observational
172
1 country
1
Brief Summary
This study evaluates the prevalence of delayed chemotherapy induced nausea in adult oncology patients in real clinical practice of day clinics.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 25, 2020
CompletedFirst Posted
Study publicly available on registry
April 13, 2020
CompletedStudy Start
First participant enrolled
June 29, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2022
CompletedApril 19, 2024
April 1, 2024
1.9 years
March 25, 2020
April 17, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
delayed Nausea
nausea that occurs 24 hours to 5 days after chemotherapy (100mm VAS in diary)
Each patient: each days for 5 days after chemotherapy; recruitment: six weeks
Secondary Outcomes (6)
acute nausea
Each patient: at day of chemotherapy at discharge from dayclinic; recruitment: six weeks
acute and delayed vomiting
Each patient: each day for 5 days after chemotherapy; recruitment: six weeks
adherence to antiemetics
Each patient: each day for 5 days after chemotherapy; recruitment: six weeks
antiemetic prescription
Each patient: at day of chemotherapy at discharge from dayclinic; recruitment: six weeks
interference of nausea or vomiting with everyday life
Each patient: measured at day 5 after chemotherapy; recruitment: six weeks
- +1 more secondary outcomes
Eligibility Criteria
Adult oncology patients in dayclinics
You may qualify if:
- first day of chemotherapy of a new cycle (any cycle)
- speak and write German
- sign the consent forms
You may not qualify if:
- cognitive or linguistic impairments that would significantly impede consent or participation (as assessed by the nurses in charge)
- accompanying radiotherapy;
- pre-existing nausea within three days before the start of the first chemotherapy in this cycle; and
- prior participation in CINrate (each person participates only once)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Antje Kollerlead
- ZETUP St. Gallencollaborator
- Dr.-Hans-Altschüler-Stiftungcollaborator
- University Medical Center Freiburgcollaborator
- Spital Thurgau AGcollaborator
Study Sites (1)
ZeTuP
Sankt Gallen, 9000, Switzerland
Related Publications (1)
Engst R, Glaus A, Moessner U, Ott S, Koller A. Delayed Chemotherapy-Induced Nausea - A Nurse-Led International Observational Study in Routine Oncology Practice (CINrate). SAGE Open Nurs. 2025 Dec 2;11:23779608251398116. doi: 10.1177/23779608251398116. eCollection 2025 Jan-Dec.
PMID: 41356791DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Antje Koller
Ostschweizer Fachhochschule St. Gallen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 25, 2020
First Posted
April 13, 2020
Study Start
June 29, 2020
Primary Completion
May 31, 2022
Study Completion
May 31, 2022
Last Updated
April 19, 2024
Record last verified: 2024-04